Here in the UK we’ve already seen thefirst people receiving the Pfizer/BioNTech vaccine on the NHS, with others likely to follow soon. Given the pace of development and testing, it’s not surprising that some people might worry that safety has been sacrificed for speed. We spoke withDr J...
“There is early evidence that the lockdown is starting to bring cases down but we are a long, long, long way from being low enough,” Hancock said on Sky. “You can see the pressure on the NHS, you can see it every day.” ALSO READ:AstraZeneca to cut deliveries of its virus va...
Colorectal cancer (CRC) is a common cancer in the world and also has a high death rate. It is reported that vaccination is a great strategy for CRC. CRC vaccines are based on CRC tumor antigens, including tumor-associated antigens like CEA, MUC-1, CTAs and tumor-specific antigens includ...
Back in December, Health Secretary Matt Hancock spoke of the NHS beingready “to inject hope into millions of arms this winter”– referring, of course to the vaccines. As Christians, we mustn’t be swept into thinking that vaccines are our great hope. Even if we grant that they are whol...
Funding: This study was funded through the NHS Executive South East research and development project grant scheme. Additional support was provided by Becton Dickinson. JJD is supported by a Department of Health National Coordinating Centre for Research Capacity Development senior research fellowship in ev...
The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in...
Multivalent antigen display on nanoparticles can enhance the immunogenicity of nanovaccines targeting viral moieties, such as the receptor binding domain (RBD) of SARS-CoV-2. However, particle morphology and size of current nanovaccines are significantly
vivax is rarely lethal, efforts to prevent and treat malaria have been focused on the more deadly form of the disease caused by Plasmodium falciparum (P. falciparum). Although the disease caused by P. vivax does not usually result in death of the patient, due to the volume of cases, ...
Therapeutic vaccination is a promising intervention for hepatitis B as a way to induce immune control over the disease. T-cell responses have been shown to be critical for clearance of acute HBV infection. However, therapeutic HBV vaccines based on HBsAg have failed to show benefit due to ...
Building on this rationale, we provide a comprehensive overview on emerging cancer glycovaccines, emphasizing the potential of nanotechnology in this context. A roadmap towards clinical implementation is also delivered foreseeing advances in glycan-based immunomodulatory cancer medicine. Graphical abstract ...